Table 3:

Estimated mean prostate volume¹ over the REDUCE trial period according to statin use, overall and by treatment arm

	Baseline	Year 2	Year 4
All patients
Overall	45.6 (45.1–46.2)	45.5 (45.0–46.0)	48.6 (48.0–49.1)
Non-statin user	45.7 (45.2–46.3)	45.8 (45.2–46.4)	48.9 (48.3–49.4)
Statin user	45.3 (44.0–46.5)	44.0 (42.8–45.3)	47.2 (45.9–48.6)
Placebo arm
Overall	45.6 (44.9–46.4)	51.9 (51.1–52.6)	58.0 (57.2–58.8)
Non-statin user	45.7 (44.9–46.5)	52.1 (51.4–52.9)	58.3 (57.4–59.1)
Statin user	45.2 (43.8–46.6)	50.4 (49.0–51.8)	56.6 (55.2–58.1)
Dutasteride arm
Overall	45.7 (44.9–46.4)	39.6 (38.9–40.3)	39.8 (39.1–40.6)
Non-statin user	45.7 (45.0–46.5)	39.9 (39.1–40.6)	40.1 (39.3–40.9)
Statin user	45.3 (43.9–46.6)	38.1 (36.8–39.5)	38.5 (37.1–39.9)

¹measured in cc and represented as mean (95% CI); prostate volume estimates were derived from the GEE model presented in Table 2